Informace o projektu
Excellence in research and development of non-coding RNA DIAGnostics in ONcology
(RNADIAGON)
- Kód projektu
- 824036
- Období řešení
- 2/2019 - 7/2024
- Investor / Programový rámec / typ projektu
-
Evropská unie
- Horizon 2020
- MSCA Marie Skłodowska-Curie Actions (Excellent Science)
- Fakulta / Pracoviště MU
- Středoevropský technologický institut
- Spolupracující organizace
-
Universita degli studi di Ferrara
BioVendor - Laboratorní medicína, a.s.
Medizinische Universität Graz
Universitätsklinikum Hamburg-Eppendorf
Universitatea de Medicină şi Farmacie
University of Texas MD Anderson Cancer Center
Project RNADIAGON aims at development of personal skills and knowledge of early-stage and experienced researchers working in the field of non-coding RNA diagnostics in oncology from 5 European (EU) academic centers (Masaryk University, CEITEC, Czech Republic; University Medical Center Hamburg-Eppendorf, Germany; Iuliu Hatieganu University of Medicine and Pharmacy, Romania; University of Ferrara, Italy; Medical University of Graz, Austria) through their (i) long-term stays at the US research center of excellence (MD Anderson Cancer Center, University of Texas, USA) and (ii) traineeships at the education center and manufacturing facilities of industrial partner (BioVendor, Inc.) developing certified (CE IVD) diagnostics, who will work on the development of a new non-coding RNA diagnostic kit in colorectal cancer adopted here as a model project. This research and innovation staff exchange will increase the scientific excellence and quality of related research in the participating EU research institutions, and enable the dissemination of new technologies and approaches related to this field among other EU research institution as well as interested public.
Cíle udržitelného rozvoje
Masarykova univerzita se hlásí k cílům udržitelného rozvoje OSN, jejichž záměrem je do roku 2030 zlepšit podmínky a kvalitu života na naší planetě.
Publikace
Počet publikací: 10
2023
-
Combination of Urinary MiR-501 and MiR-335 With Current Clinical Diagnostic Parameters as Potential Predictive Factors of Prostate Biopsy Outcome
CANCER GENOMICS & PROTEOMICS, rok: 2023, ročník: 20, vydání: 3, DOI
2021
-
circFOXO3: Going around the mechanistic networks in cancer by interfering with miRNAs regulatory networks
Biochimica et Biophysica Acta - Molecular Basis of Disease, rok: 2021, ročník: 1867, vydání: 5, DOI
2020
-
Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers
Frontiers in Cell and Developmental Biology, rok: 2020, ročník: 8, vydání: SEP, DOI
-
lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System
Cancers, rok: 2020, ročník: 12, vydání: 8, DOI
-
Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer
Cancers, rok: 2020, ročník: 12, vydání: 5, DOI
-
Tiny Actors in the Big Cellular World: Extracellular Vesicles Playing Critical Roles in Cancer
International Journal of Molecular Sciences, rok: 2020, ročník: 21, vydání: 20, DOI
2019
-
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Cancers, rok: 2019, ročník: 11, vydání: 10, DOI
-
Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma
Cancers, rok: 2019, ročník: 11, vydání: 10, DOI
-
Evaluation of miRNA detection methods for the analytical characteristics necessary for clinical utilization
Biotechniques, rok: 2019, ročník: 66, vydání: 6, DOI
-
Prognostic Value of MiR-21: An Updated Meta-Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC)
Journal of Clinical Medicine, rok: 2019, ročník: 8, vydání: 12, DOI